Beam Therapeutics filed suit alleging theft of base editing trade secrets by a former scientist and new Chinese rivals, with Beam claiming its proprietary technology was used to develop a competing therapy. The complaint targets YolTech and Serapha Bio, and it alleges that confidential information tied to Beam’s alpha-1 antitrypsin deficiency program was incorporated into the defendants’ work. The litigation adds another chapter to ongoing U.S.-China tensions in genomic medicine, where IP protection and competitive duplication claims increasingly shape investor sentiment and deal terms. YolTech and Serapha deny wrongdoing. For the industry, the case raises execution risk for teams that rely on rapid transfer of platform learnings and for investors who must underwrite IP defensibility alongside scientific merit.